title: Effect of hyperlipidemia on 11β-hydroxysteroid-dehydrogenase, glucocorticoid receptor, and leptin expression in insulin-sensitive tissues of cats.
abstract: Glucocorticoid (GC) action depends on GC plasma concentration, cellular GC receptor expression, and the pre-receptor hormone metabolism catalyzed by 11β-hydroxysteroid dehydrogenase (11β-HSD). 11β-Hydroxysteroid dehydrogenase exists in 2 isoforms; 11β-HSD1 converts inactive cortisone to cortisol, and 11β-HSD2 converts cortisol to cortisone. Increasing evidence in humans and experimental animals suggests that altered tissue cortisol metabolism may predispose to diabetes mellitus (DM). Once DM is established, hyperglycemia and hyperlipidemia may further maintain the abnormal metabolism of cortisol. To gain further insight in this regard, healthy cats were infused for 10 d with lipids (n = 6) or saline (n = 5). At the end of the infusion period, tissue samples from adipose tissue (visceral, subcutaneous), liver, and muscle were collected to determine mRNA expression of 11β-HSD1, 11β-HSD2, and GC receptor by real-time reverse-transcriptase polymerase chain reaction; blood samples were collected to determine plasma cortisol and leptin concentrations. Lipid infusion resulted in greater 11β-HSD1 expression and lower GC receptor expression in visceral and subcutaneous adipose tissue, and lower 11β-HSD2 expression in visceral adipose tissue and liver. Plasma cortisol did not differ. Leptin and body weight increased in lipid-infused cats. In spite of comparable circulating cortisol levels, up-regulation of 11β-HSD1 and down-regulation of 11β-HSD2 expression may result in increased tissue cortisol concentrations in fat depots of hyperlipidemic cats. Down-regulation of GC receptor may represent a self-protective mechanism against increased tissue cortisol levels. In conclusion, hyperlipidemia has a profound effect on 11β-HSD expression and supports the connection between high lipid concentrations and tissue cortisol metabolism.
authors.affiliation: Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland. nsieber@vetclinics.uzh.ch
authors.forename: Nadja S
authors.initials: NS
authors.lastname: Sieber-Ruckstuhl
authors.forename: Eric
authors.initials: E
authors.lastname: Zini
authors.forename: Melanie
authors.initials: M
authors.lastname: Osto
authors.forename: Marco
authors.initials: M
authors.lastname: Franchini
authors.forename: Felicitas S
authors.initials: FS
authors.lastname: Boretti
authors.forename: Marina L
authors.initials: ML
authors.lastname: Meli
authors.forename: Brigitte
authors.initials: B
authors.lastname: Sigrist
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Lutz
authors.forename: Claudia E
authors.initials: CE
authors.lastname: Reusch
mesh_terms: D042842:11-beta-Hydroxysteroid Dehydrogenases / Q000235:genetics*; D000273:Adipose Tissue / Q000737:chemistry; D000818:Animals; D002371:Cat Diseases / Q000378:metabolism*; D002415:Cats; D005230:Fatty Acids, Nonesterified / Q000097:blood; D015870:Gene Expression; D005938:Glucocorticoids / Q000097:blood; D005951:Glucose Tolerance Test / Q000662:veterinary; D006854:Hydrocortisone / Q000032:analysis / Q000097:blood; D006949:Hyperlipidemias / Q000209:etiology / Q000378:metabolism / Q000662:veterinary*; D007328:Insulin / Q000097:blood / Q000494:pharmacology; D020738:Leptin / Q000097:blood / Q000235:genetics*; D008055:Lipids / Q000008:administration & dosage; D008099:Liver / Q000737:chemistry; D008297:Male; D009132:Muscles / Q000737:chemistry; D012333:RNA, Messenger / Q000032:analysis; D011965:Receptors, Glucocorticoid / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D005230:Fatty Acids, Nonesterified; D005938:Glucocorticoids; D007328:Insulin; D020738:Leptin; D008055:Lipids; D012333:RNA, Messenger; D011965:Receptors, Glucocorticoid; D042842:11-beta-Hydroxysteroid Dehydrogenases; D006854:Hydrocortisone